Evidence map›Paper›PMID 37853294›Full record

ArticleUpdates in surgery2024

The effect of platelet-to-lymphocyte ratıo (PLR) and glasgow prognostıc score (GPS) on recurrence, and survıval ın patıents undergoıng lobectomy for early-stage non-small cell lung cancer (NSCLC).

Bahar Agaoglu Sanli, Barıs Gulmez, Serkan Yazgan, Ahmet Ucvet

Abstract read
PubMed Publisher
In one paragraph

Article in Updates in surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bahar Agaoglu SanliDr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, University of Health Sciences Turkey, Izmir, Turkey. drbaharagaoglu@hotmail.com.ORCID http://orcid.org/0000-0001-8462-6059
Barıs GulmezVan Training and Research Hospital, Thoracic Surgery Clinic, University of Health Sciences Turkey, Van, Turkey.ORCID http://orcid.org/0000-0002-4047-8960
Serkan YazganDr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, University of Health Sciences Turkey, Izmir, Turkey.ORCID http://orcid.org/0000-0001-9763-6336
Ahmet UcvetDr Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital, University of Health Sciences Turkey, Izmir, Turkey.ORCID http://orcid.org/0000-0002-5649-560X
Izmir University · TRMinistry of Health · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor markers are indicators that can be used not only for cancer diagnosis but also for determining prognosis. Unfortunately, there is currently no tumor marker that reliably predicts the prognosis of lung cancer. In this study, we investigated the prognostic impact of the platelet-to-lymphocyte ratio (PLR) and Glasgow Prognostic Score (GPS), known as inflammation markers in peripheral blood, in patients who underwent resection for early-stage non-small cell lung cancer (NSCLC). We retrospectively analyzed the medical records of a total of 3300 patients who underwent surgery for NSCLC between 2010 and 2020. Among these patients, 250 met the inclusion criteria of lobectomy, pT1-T2N0 stage, and histology of adenocarcinoma or squamous cell carcinoma. Preoperative albumin, C-reactive protein (CRP), preoperative PLR, and postoperative 5th-day PLR values were determined from patient's peripheral blood data. The impact of these values on postoperative recurrence and survival was investigated. GPS was calculated based on preoperative CRP and albumin values, and patients were divided into 3 groups: 0 (mild), 1 (moderate), and 2 (severe). The relationship between preoperative GPS and survival was analysed. Among the included patients, 155 (62%) had adenocarcinoma and 95 (38%) had squamous cell carcinoma. A total of 185 (74%) patients had pT1 tumors, while 65 (26%) had pT2 tumors. During the postoperative follow-up period, local recurrence was observed in 28 (11.2%) patients and distant metastasis in 51 (20.4%) patients. The overall mortality rate was 19.6%. The 5-year survival rates for pT1 and pT2 tumors were 80.4% and 72.5%, respectively. Significant associations were found between preoperative PLR, postoperative PLR, and recurrence (p = 0.005 and p = 0.011). The expected overall survival (OS) was 103.4 months in the mild GPS group, 91.8 months in the moderate GPS group, and 50 months in the severe GPS group. The relationship between GPS groups and OS was statistically significant (p = 0.005). Preoperative analysis of PLR and GPS may provide prognostic value in NSCLC patients who undergo surgical resection. Our study provides a rationale for further investigation of peripheral blood immune markers for prognostic purposes.

Indexed as

AdenocarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsBiomarkers, TumorC-Reactive ProteinHumansLymphocytesPrognosisRetrospective StudiesBiomarkers, TumorC-Reactive ProteinGlasgow prognostic scoreNon-small cell lung cancerPlatelet-to-lymphocyte ratio

Identifiers

PMID37853294
OpenAlexW4387735257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.